Eyeworld

OCT 2014

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/387844

Contents of this Issue

Navigation

Page 121 of 164

117 EW RETINA October 2014 As for the fellow eye, observa- tions from long-term studies may shed better light on the natural history of AMD and visual progno- sis. "Ongoing analyses will evaluate the development of new choroidal neovascularization in the fellow eyes among patients in the VIEW studies," Dr. Korobelnik said. EW Editors' note: Dr. Korobelnik has financial interests with Alcon (Fort Worth, Texas), Allergan (Irvine, Calif.), Bayer (Leverkusen, Germany), Novar- tis (Basel, Switzerland), Roche (Basel, Switzerland), Thea (Clermont-Ferrand, France), and Carl Zeiss Meditec (Jena, Germany). Dr. Marcus has financial interests with Acucela (Seattle), Alcon, Allergan, Genentech (South San Fran- cisco), GlaxoSmithKline (Brentford, U.K.), Ophthotech (New York), Pfizer (New York), Regeneron (Tarrytown, N.Y.), and ThromboGenics (Leuven, Belgium). Contact information Korobelnik: jean-francois.korobelnik@chu-bordeaux.fr Marcus: dmarcus@southeastretina.com of the combined VIEW 1 and 2 data sets comprising 2,412 patients. They recently described the baseline char- acteristics of these eyes as a first step to assessing change over time. As expected, visual acuity in fellow eyes was better than in study eyes by just over 11 ETDRS letters. Overall, two-thirds of fellow eyes had acuity of 66 letters or more, compared to just 20% of study eyes. "The majority of fellow eyes had signs of AMD at baseline," said Dr. Korobelnik. A full 90% had hard and/or soft drusen, and 88% had pigment changes in the subfoveal or extrafoveal regions. "Also, 35% of fellow eyes had clinical signs of prior choroidal neovascularization at baseline," he said. Practical implications AMD is a lifelong disease. As the long-term extension of the VIEW 1 study demonstrates, there is slow but steady attrition of visual acuity over time even in eyes treated with a proven effective therapy. Tools to assess the risk of blindness from AMD have not been developed or validated. However, this long-term observation may assist physicians in counseling the patients who inevita- bly ask, "Doctor, will I go blind from this disease?" XXXIII Congress of the ESCRS 5 – 9 September 2015 Barcelona, Spain www.escrs.org Instructional Course Submission Deadline 31 October 2014 Intravitreal injection into the pars plana Source: Karl Brasse, MD, EyeLand Design

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - OCT 2014